Skip to Content

Pharming Group PHARM

Morningstar Rating
€0.83 −0.01 (1.24%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PHARM is trading at a 491% premium.
Price
€0.85
Fair Value
€2.82
Uncertainty
High
1-Star Price
€6.34
5-Star Price
€8.64
Economic Moat
Rxj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHARM is a good fit for your portfolio.

News

Trading Information

Previous Close Price
€0.85
Day Range
€0.830.85
52-Week Range
€0.831.31
Bid/Ask
€0.83 / €0.84
Market Cap
€561.98 Mil
Volume/Avg
3.6 Mil / 6.5 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.59
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
382

Comparables

Valuation

Metric
PHARM
NAMS
PHVS
Price/Earnings (Normalized)
Price/Book Value
2.984.322.87
Price/Sales
2.59242.43
Price/Cash Flow
Price/Earnings
PHARM
NAMS
PHVS

Financial Strength

Metric
PHARM
NAMS
PHVS
Quick Ratio
1.168.1320.11
Current Ratio
1.438.1720.53
Interest Coverage
−2.66
Quick Ratio
PHARM
NAMS
PHVS

Profitability

Metric
PHARM
NAMS
PHVS
Return on Assets (Normalized)
−3.79%−39.62%−29.37%
Return on Equity (Normalized)
−8.05%−46.06%−31.42%
Return on Invested Capital (Normalized)
−4.58%−48.63%−32.27%
Return on Assets
PHARM
NAMS
PHVS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLtcskkvbgJgd$586.3 Bil
VRTX
Vertex Pharmaceuticals IncHxnxdbmpWxjbb$113.7 Bil
REGN
Regeneron Pharmaceuticals IncVkqkwqwcHtkdhz$108.2 Bil
MRNA
Moderna IncHdfjrkbmDghb$50.9 Bil
ARGX
argenx SE ADRCsrtqjzyGmz$22.0 Bil
BNTX
BioNTech SE ADRMqjvjljkNmybv$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncClppmqvqSwvvxn$18.9 Bil
BMRN
Biomarin Pharmaceutical IncZbbzyfvGmbkm$14.6 Bil
INCY
Incyte CorpFlqhttcCfhlbnx$12.8 Bil
RPRX
Royalty Pharma PLC Class ADkmvznlbdZcszps$12.3 Bil

Sponsor Center